PeptidePicker
Home/Peptides/TB-500
RecoveryResearch

TB-500

Also known as: Thymosin Beta-4 fragment · TB4

A synthetic fragment of thymosin beta-4, studied for systemic tissue repair and anti-inflammatory effects. Often paired with BPC-157 as the 'Wolverine Stack' for injury recovery.

Dr. Sarah Mitchell

Reviewed by Dr. Sarah Mitchell, PharmD, BCPS

Lead Researcher · 12+ years in peptide therapeutics

Half-Life

~2 hours (active metabolites longer)

Typical Dose

2.5–5 mg twice weekly

Administration

Subcutaneous injection

Mechanism of Action

Upregulates actin polymerization and cell migration, promoting angiogenesis and reducing inflammation to facilitate soft tissue regeneration throughout the body.

Key Research Areas

healingrecoveryinflammationtissue repairwolverine stack

Frequently Asked Questions

What is TB-500?
A synthetic fragment of thymosin beta-4, studied for systemic tissue repair and anti-inflammatory effects. Often paired with BPC-157 as the 'Wolverine Stack' for injury recovery.
How does TB-500 work?
Upregulates actin polymerization and cell migration, promoting angiogenesis and reducing inflammation to facilitate soft tissue regeneration throughout the body.
What is the recommended dosage for TB-500?
The typical research dosage is 2.5–5 mg twice weekly, administered via Subcutaneous injection. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of TB-500?
The half-life of TB-500 is approximately ~2 hours (active metabolites longer). This affects dosing frequency and timing in research protocols.
Is TB-500 FDA approved?
TB-500 is currently classified as "Research" and is not FDA approved for general use. It is available for research purposes or through compounding pharmacies depending on your jurisdiction.

Research Disclaimer

The information provided about TB-500 is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.

Related Peptides in Recovery